Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal of Translational Medicine

Fig. 4

From: PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

Fig. 4

BKM120 inhibits PI3K but not mTOR pathway downstream effectors in LMS cells. Immunoblot demonstrating decreased levels of p-AKTS473, but not in p-4EBP1T37/46 in total lysates from SKLMS1 and STS39 cells treated with BKM120. SKLMS1 cells were treated for 72 h at concentrations ranging from 0 to 1000 nM/L. Total AKT, 4EBP1 and tubulin levels are shown for loading control

Back to article page